A 13-year real-life study on efficacy, safety and biological effects of venom immunotherapy.

Background: venom immunotherapy (VIT) is a clinically effective treatment. However, little is known about its long-term clinical efficacy and biological effects. Several mechanisms have been proposed to account for VIT efficacy, including reduction of specific IgE and induction of allergen-specific IgG, but the overall picture remains elusive.

Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.

Background: Randomized Controlled Trials showed that omalizumab exhibited a good safety and tolerability profile in patients with moderate-to-severe asthma. However, safety data of long-term treatment with omalizumab are scarce. Our aim was to assess the safety of omalizumab in patients under long-term treatment in a real-life setting.